To our knowledge, this is the first study to assess the potential risk of injection-related ptosis by comparing MRD1 measurements in patients who underwent unilateral anti-VEGF IVI over 12 months with those of their non-injected fellow eyes. This evidence concerns the gene VEGFA and ptosis.